MedTrace Logo

Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients

NCT04059029 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-08-16

No results posted yet for this study

Summary

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver biochemistry tests in the world. The prevalence rate of NAFLD has been reported to be 30-40% in men and 15-20% in women, up to 70% of people with type 2 diabetes mellitus (Type 2 DM) and even surpassing 74% to 90% of morbidly obese patients with body mass index (BMI) higher than 35 kg/m\^2. The primary aims of this prospective cohort study would evaluate the predictive factors of successful weight reduction, NAFLD and nonalcoholic steatohepatitis (NASH) improvement in a large cohort of morbidly obese patients undergoing bariatric surgery. Secondarily, the diagnostic accuracy of noninvasive serum markers, doppler ultrasonography and transient elastography would be validated. Thirdly, we would conduct gene expression analyses to elucidate biological pathways underlying NAFLD phenotypes in this unique cohort.

Conditions

  • Nonalcoholic Fatty Liver Disease (NAFLD)

Interventions

PROCEDURE

Bariatric surgery

During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.

Sponsors & Collaborators

  • Taipei Medical University Hospital

    lead OTHER

Principal Investigators

  • Weu Wang, M.D.&PhD · Comprehensive weight management center, Taipei Medical University hospital

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-07-31
Completion
2021-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04059029 on ClinicalTrials.gov